Pricing Log in Create free account

uniQure N.V. (QURE) vs Ultragenyx Pharmaceutical Inc. (RARE)

uniQure N.V. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. uniQure N.V. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.6B and $1.5B). uniQure N.V. grew revenue faster over the last twelve months: 30.2% against 17.5%. Ultragenyx Pharmaceutical Inc. has the higher net margin (−81.7% vs −1,350.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Ultragenyx Pharmaceutical Inc. leads on 9 and uniQure N.V. on 7.

Valuation

Metric QURE RARE Biotechnology median
P/E n/m n/m 8.50
P/S 77.06 2.07 9.71
P/B 4.44 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 36.79 1.66 9.21
Earnings yield (18.46%) (40.17%) (33.15%)
Free cash flow yield (11.37%) (33.34%) (25.50%)

Profitability

Metric QURE RARE Biotechnology median
Gross margin 92.49% 83.12% 65.16%
Operating margin (1,071.53%) (73.64%) 0.00%
Net margin (1,350.73%) (81.73%) 0.00%
Free cash flow margin (864.67%) (68.90%) 0.00%
Return on equity (157.61%) 838.86% (56.36%)
Return on assets (32.13%) (45.60%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric QURE RARE Biotechnology median
Revenue growth (TTM) 30.24% 17.51% 6.02%
EPS growth (last fiscal year) 29.67% 7.31% 30.26%
Revenue growth, 5-year CAGR (15.57%) 19.95% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric QURE RARE Biotechnology median
Debt to equity 0.15 0.00 0.00
Current ratio 10.01 1.73 4.72
Net debt to EBITDA 3.36 1.35 0.96

Dividend

Metric QURE RARE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric QURE RARE Biotechnology median
Market cap 1.56b 1.50b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack